Furthermore, Goswami et al. showed that the absence of CD73 improved the efficacy of combined treatment with antibodies targeting immune checkpoint proteins cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4) and PD-1, resulting in prolonged survival in a murine model of GBM [88]. This evidence concerns the gene CTLA4 and glioblastoma.